Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides

AU2026210856A1Pending Publication Date: 2026-08-20THE GENERAL HOSPITAL CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
AU2026210856
Authority / Receiving Office
AU · AU
Patent Type
Applications
Current Assignee / Owner
Filing Date
2026-08-01
Publication Date
2026-08-20

Smart Images

  • Figure 00000205_0000
    Figure 00000205_0000
  • Figure 00000206_0000
    Figure 00000206_0000
  • Figure 00000207_0000
    Figure 00000207_0000
Patent Text Reader

Abstract

Abstract Described are antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T- regs) and / or myeloid- derived suppressor cells (MDSCs), to expand T effector cell populations or function, and to reduce the proliferation of, or directly kill, tumor cells, such as tumor cells that express TNFR2 antigen. The polypeptides, such as antibodies and antigen-binding fragments thereof, are TNFR2 antagonists, such as dominant TNFR2 antagonists. The polypeptides can be used to suppress the T-reg- or MDSC-mediated deactivation of tumor reactive T lymphocytes, expand populations of tumor-reactive cytotoxic T cells, and / or to directly kill TNFR2+ tumor cells. The antagonistic TNFR2 polypeptides described herein can be used to treat a wide variety of cancers and infectious diseases. Abstract
Need to check novelty before this filing date? Find Prior Art